Researchers from Johns Hopkins Medicine and Yale University have collaborated on the development and application of a ...

A range of medications are available to help treat lupus nephritis (LN), each offering a specific role in managing the ...

Amit Saxena, MD, discusses how evidence-based guidelines from ACR and KDIGO have evolved to shape lupus nephritis treatment approaches, emphasizing their critical role in standardizing patient care ...

1 The purpose of ALMS was to demonstrate the superiority of mycophenolate mofetil (MMF) over intravenous cyclophosphamide for the induction of remission in patients with lupus nephritis.

Multiple Key Leadership Appointments, Including Warner Biddle as CEO, Bringing Clinical, Commercial and Strategic Expertise in Cell Therapy Continuing to Advance Broad ...

Lupus nephritis is an inflammatory kidney disease (glomerulonephritis) that develops in patients with systemic lupus erythematosus (SLE). In patients with SLE, the immune system is not properly ...

The Lupus Foundation of America (LFA) is proud to honor two exceptional lupus researchers at the 2024 Evelyn V. Hess ...

The FDA told the San-Francisco based biotech to halt the PALIZADE study (NCT05781750), a Phase IIb trial investigating ...

Researchers from both Johns Hopkins Medicine and Yale University collaborated on the development and application of a diagnostic model to detect acute interstitial nephritis (AIN) in patients, which c ...

Attendees can also look forward to the unveiling of new lupus nephritis guidelines, reflecting over a year of effort by experts. Additionally, there will be sessions on the potential of cell ...

Panelists discuss the significant clinical and economic burdens of lupus nephritis, including the increased risk of kidney failure and death, and provide current statistics on the prevalence and ...

(Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today ...